Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
Clinical Pediatrics
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Gunay, U.
Right arrow Articles by Honig, G. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gunay, U.
Right arrow Articles by Honig, G. R.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*PROCAINAMIDE
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Agranulocytosis in a 12-Year-Old Girl Treated with Procainamide

Unsal Gunay

U.S. Public Health Service graduate trainee in pediatric hematology, Department of Pediatrics, University of Illinois Medical Center, Abraham Lincoln School of Medicine, 840 South Wood Street, Chicago, Ill. 60612

George R. Honig

National Institute of Arthritis, Metabolism, and Digestive Diseases, Abraham Lincoln School of Medicine

A 12-year old girl developed transitory agranulocytosis 13 days after treat ment with procainamide for arrythmia was begun. The white cell count and differential returned rapidly to normal with complete clinical recovery after procainamide was discontinued. Agranulocytosis, a rare and serious complica tion of procainamide therapy, has a high mortality rate. Patients re ceiving this drug should be observed closely and followed with frequent blood counts.

Clinical Pediatrics, Vol. 13, No. 9, 728-730 (1974)
DOI: 10.1177/000992287401300905
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Arch Intern MedHome page
L. Giannone, J. W. Kugler, and S. B. Krantz
Pure Red Cell Aplasia Associated With Administration of Sustained-Release Procainamide
Arch Intern Med, June 1, 1987; 147(6): 1179 - 1180.
[Abstract] [PDF]

Home page
 Arch Intern MedHome page
D. J. Meisner, R. J. Carlson, and A. J. Gottlieb
Thrombocytopenia Following Sustained-Release Procainamide
Arch Intern Med, April 1, 1985; 145(4): 700 - 702.
[Abstract] [PDF]